Innovations in Glaucoma: Explaining SLT and the LiGHT Trial

Due to its excellent benefit-to-risk profile, Selective Laser Trabeculoplasty, or SLT, is being offered earlier in the treatment of glaucoma, including as primary therapy. Learn about a recent major study that showed glaucoma patients receiving this simple 5-minute laser procedure did as well or better than those treated with eye drops.

Inder Paul Singh, MD, President of The Eye Centers of Racine & Kenosha, shares his insights about the benefits of Selective Laser Trabeculoplasty (SLT) for glaucoma, and Gus Gazzard, MD, Director of the Glaucoma Service at Moorfields Eye Hospital, discusses results from the “Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial,” which aimed to establish whether initial treatment with SLT is superior to initial treatment with topical medication for primary open-angle glaucoma or ocular hypertension. The webinar is moderated by Thomas M. Brunner, President and CEO of Glaucoma Research Foundation.

This recorded webinar was first presented on September 27, 2022 by Glaucoma Research Foundation.